Navigation Links
Unilife's Bolus Injector Platform Targeted by Global Pharmaceutical Company for Use in Multi-Drug Program

YORK, Pa., Nov. 8, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced that its Precision-Therapy™ platform of bolus injection systems has been selected by a global pharmaceutical company to enter the next stage of collaboration as its preferred choice for long-duration subcutaneous drug delivery.

Unilife has been advised that the global pharmaceutical company (the "Customer") is targeting more than five pipeline injectable drugs for use with the Precision-Therapy platform of bolus injectors (wearable, disposable pumps). The first of these target drugs identified by the Customer is in Phase III clinical trials.

Unilife has recently commenced the initial supply of its Precision-Therapy devices to the Customer. Initial revenues will be generated by Unilife during the current fiscal year as it supports the immediate needs of the Customer under this partnership program.

Unilife expects to enter into a development agreement with the Customer during the current fiscal year to customize Precision-Therapy devices for use in the first target drug's upcoming human clinical trials. Unilife expects the first of these development agreements to generate in excess of $10 million in revenue over an 18 to 24 month period.  Unilife expects to successively enter into a series of additional development agreements with similar terms relating to the other target drugs.

Unilife further expects that it will begin commercial supply of Precision-Therapy bolus injectors to the Customer in 2015 to support the anticipated market launch of the first target drug. Commercial supply contracts for each targeted drug under the program are expected to have an initial term of seven years. Based upon indicated customer requirements for the first drug candidate, Unilife expects to generate commercial revenues of approximately $50 million per year under an initial supply contract.

Unilife expects that it will enter into separate commercial supply contracts for each target drug brought to market by the Customer.  Across the full portfolio of target drugs identified by the Customer, Unilife expects that commercial supply revenues per drug will range between $30 million and $70 million a year.

For commercial purposes and due to confidentiality clauses within the agreement, additional terms of the contract and the identity of the pharmaceutical company are to remain confidential at this time.

Mr. Alan Shortall, CEO of Unilife, said, "Our Precision-Therapy platform of bolus injectors and Flex-Therapy platform of infusion pumps are consistently being identified by pharmaceutical companies as the preferred technology for the long-duration subcutaneous delivery of injectable drugs.

"It is important to note that today's announcement regarding the selection of our bolus injection platform by a global pharmaceutical company follows an extensive evaluation process involving many of our device competitors. The customer has advised that their rationale for the selection of Unilife was our deep industry expertise, advanced operational capabilities, strong patent position and ability to consistently exceed program requirements. They believe our superior device technology will represent a major part of the value proposition to support the successful commercial launch of a series of injectable therapies that currently reside within their clinical pipeline.

"The platform-based approach we have utilized in the development of our Precision-Therapy bolus injectors means that we will play an integral role in the clinical development, regulatory approval and commercial success of a broad portfolio of injectable therapies under a long-term collaboration with this customer.

"We look forward to the signing of an initial development agreement this fiscal year to customize a device from our Precision-Therapy platform that will address the specific needs of this customer for the first of their target drugs. I expect each commercial supply contract that we sign under this program can ultimately generate hundreds of millions of dollars in cumulative revenues during its full term. Such long-term collaborations underpin the strength of the strategic relationships that we continue to build with a number of pharmaceutical companies for drug-device combination products.

"This marks the start of a multi-stage, multi-drug long-term partnership with this global pharmaceutical company. However it is just one of many exciting opportunities that now reside within our fast-expanding commercial pipeline. We look forward to entering into similar partnerships with other pharmaceutical companies that are now at various stages in the evaluation and selection of devices from our broad portfolio of technology platforms that will enable and enhance their target pipeline and approved drugs," Mr. Shortall concluded.

Precision-Therapy Bolus Injector Platform and Flex-Therapy Infusion Pump PlatformUnilife has developed the Precision-Therapy platform of bolus injectors and Flex-Therapy platform of infusion pumps to help enable and enhance bolus or rate-based injectable therapies that require the long-duration subcutaneous delivery of doses between 1mL and 30mL in volume. Featuring a primary container with standard materials in the fluid path, they are designed for integration into existing fill-finish lines and can be customized to address specific customer or patient needs including dose volume, delivery rate and duration, drug viscosity, and ergonomic design. Compact in size and highly intuitive for use, they can be comfortably worn on or off the body of a patient during the designated dose duration. Patients simply push a button to commence the automatic delivery of the dose via a soft, indwelling catheter. Visual and audible electronic indicators communicate with the patient during each stage of use. Upon the delivery of the full dose, the device can be removed from the body for convenient disposal.

About Unilife Corporation Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. The Unifill® syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of a broad portfolio of innovative, highly differentiated devices. In addition to prefilled syringes with automatic needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, bolus injectors, infusion pumps and targeted delivery systems. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.comForward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor Contacts (US):
Analyst Enquiries 

Investor Contacts (Australia)

Media ContactTodd Fromer / Garth Russell 

Lynn Pieper 

Jeff CarterEve McGrathKCSA Strategic CommunicationsWestwicke Partners 

Unilife CorporationRubenstein PRP: + 1 212-682-63P: + 1 415-202-5678P: + 61 2 8346 6500 

P: + 1 212 843-8490 

SOURCE Unilife Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
2. Bausch + Lomb Product, Platform and Pipeline Innovations on Display at the Annual Meeting of the American Academy of Ophthalmology
3. Greenphires ClinCard Technology Platform selected by top 5 pharmaceutical company for long-term global clinical trial
4. Advantages of Pressure BioSciences PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
5. CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform to Bolster Expanded Lab Operations
6. Keynote Presentation at Upcoming International Microbiology & Genomics Meeting to Highlight Ability of Pressure BioSciences Patented PCT Platform to Improve Testing for Biological Threat Organisms, Human Infectious Diseases, and Contaminated Food P
7. Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
8. Lincor Solutions Launches Next Generation Bedside Point of Care Computing Platform at HIMSS AsiaPac 12
9. Indegene Introduces TrialPedia 2.0 with Advantage Insights, Making It the Most Comprehensive Clinical Trial Analytics and Decision Support Platform for the Pharma Industry
10. Absorption Systems announces novel test platform for interactions with the BCRP transporter
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
(Date:11/29/2015)... 2015  The GE Health Cloud 1 was unveiled ... North America (RSNA) meeting in ... the new cloud ecosystem and its applications will connect radiologists ... and multidisciplinary teams – both inside and outside the hospital ... of GE. "As the digital industrial leader, we are betting ...
(Date:11/29/2015)... 29, 2015   National Decision Support Company (NDSC) ... base, including notable statewide implementations. As a result, ... ACR Select, more than 1 million times per ... ACR Select provides real-time feedback on the most ... has been implemented at over 100 healthcare systems ...
(Date:11/27/2015)... 27, 2015 --> ... go online. The potential to save costs, improve treatment ... far from fully exploited as yet. Here, particular emphasis ... either via mobile tablet or directly at the patients, ... ) -->      (Photo: ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... American Dental Association meeting in Washington D.C. revolved around the fact that proper dental ... health. The talk stressed the link between periodontal disease (more commonly referred to as ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... safe and convenient way to dispense prescription medications at home, so he invented ... way to monitor and dispense prescription medications. In doing so, it could help ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed ... 1-1 ). More than 3.7 billion people under the age of 50 – or ... to WHO's first global estimates of HSV-1 infection . , "The data shocks us ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
Breaking Medicine News(10 mins):